SCHEMBL48337

SCHEMBL48337

CS(=O)(=O)NC1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15836240 1.00 CA12 (0.58)
SCHEMBL17780256 0.89 CA12 (0.48)
SCHEMBL5586365 0.89 CA12 (0.48)
SCHEMBL8263013 0.89 CA12 (0.48)
SCHEMBL15214569 0.89 CA12 (0.48)
SCHEMBL12820397 0.89 CA12 (0.48)
SCHEMBL14922462 0.89 CA12 (0.48)
SCHEMBL1679214 0.88 CA12 (0.59)
SCHEMBL1434773 0.88
SCHEMBL12018141 0.87 CA12 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118355012-A Novel heterocyclic substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect and pharmaceutical composition containing the same 昂科比克斯有限公司 2024-07-16 CN claimed
CN-113831302-A Benzisoselenazolone derivative and preparation method and application thereof 山东大学 2021-12-24 CN claimed
US-20120301426-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-11-29 US claimed
EP-2440519-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INIHIBITOR COMPOUNDS Gilead Sciences, Inc. (US) 2012-04-18 EP claimed
WO-2010144371-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INIHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-12-16 WO claimed
US-20100310500-A1 ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-12-09 US claimed
CN-1832929-A 2, 4-pyrimidinediamines for the treatment of neoplastic diseases, inflammatory diseases and immune system disorders NOVARTIS AG (CH) 2006-09-13 CN claimed
WO-2024253476-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BRAIN TUMOR 주식회사 에스트리온 2024-12-12 WO disclosed
WO-2024253475-A1 NOVEL COMPOUND AND PREPARATION METHOD THEREFOR 주식회사 에스트리온 2024-12-12 WO disclosed
CN-118355012-A Novel heterocyclic substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect and pharmaceutical composition containing the same 昂科比克斯有限公司 2024-07-16 CN disclosed
WO-2024105363-A1 PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 CURADEV PHARMA LTD (GB) 2024-05-23 WO disclosed
WO-2024094171-A1 SUBSTITUTED AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2024-05-10 WO disclosed
WO-2024017251-A1 MACROCYCLE FOR INHIBITING AND INDUCING EGFR DEGRADATION AND PREPARATION METHOD FOR AND USE OF MACROCYCLE 江苏恒瑞医药股份有限公司 2024-01-25 WO disclosed
CN-1788001-A 2, 4-bis (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders NOVARTIS AG (CH) 2006-06-14 CN disclosed
US-20050037925-A1 3-phenoxy-4-pyridazinol derivatives and herbicide composition containing the same SANKYO AGRO COMPANY, LIMITED (JP) 2005-02-17 US disclosed
EP-1426365-A1 3-PHENOXY-4-PYRIDAZINOL DERIVATIVE AND HERBICIDE COMPOSITION CONTAINING THE SAME Sankyo Agro Company, Limited (JP) 2004-06-09 EP disclosed
EP-1337550-A2 HEPATITIS C TRIPEPTIDE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-08-27 EP disclosed
WO-2002060926-A2 HEPATITIS C TRIPEPTIDE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-08 WO disclosed
US-5864043-A CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST KARL THOMAE GMBH (DE) 1999-01-26 US disclosed
US-5541229-A ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS DR. KARL THOMAE GMBH (DE) 1996-07-30 US disclosed